Related Experiment Videos
Monoclonal antibody therapy for B-cell malignancies
1Department of Hematology, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC 20007, USA. bdc4@georgetown.edu
Seminars in Oncology
|May 25, 2006
Summary
Targeted monoclonal antibodies like alemtuzumab and rituximab are revolutionizing lymphoid malignancy treatment, offering new hope beyond traditional chemotherapy. Research is optimizing their use and exploring novel antibody combinations for better patient outcomes.
Area of Science:
- Hematology
- Oncology
- Immunotherapy
Background:
- Chemotherapy was the sole treatment for advanced lymphoid malignancies for decades.
- Monoclonal antibodies represent a significant advancement in treating these cancers.
Purpose of the Study:
- To review the evolving role of monoclonal antibodies in lymphoid malignancies.
- To highlight the impact of alemtuzumab and rituximab on treatment paradigms.
Main Methods:
- Review of current clinical applications and ongoing research of monoclonal antibodies.
- Analysis of treatment outcomes and future directions in lymphoid malignancy therapy.
Main Results:
- Alemtuzumab is increasingly used in early chronic lymphocytic leukemia and in stem cell transplantation.
- Rituximab is a standard treatment for most B-cell malignancies, with ongoing research to optimize its use.
- Newer antibodies and combination regimens are under development.
Conclusions:
- Monoclonal antibodies have transformed lymphoid malignancy treatment.
- Further research into novel antibodies and combination therapies holds promise for improved cure rates.